HRP20210799T1 - Oralno terapijsko sredstvo za štitnjaču - Google Patents
Oralno terapijsko sredstvo za štitnjaču Download PDFInfo
- Publication number
- HRP20210799T1 HRP20210799T1 HRP20210799TT HRP20210799T HRP20210799T1 HR P20210799 T1 HRP20210799 T1 HR P20210799T1 HR P20210799T T HRP20210799T T HR P20210799TT HR P20210799 T HRP20210799 T HR P20210799T HR P20210799 T1 HRP20210799 T1 HR P20210799T1
- Authority
- HR
- Croatia
- Prior art keywords
- therapeutic agent
- thyroid
- oral therapeutic
- active ingredient
- alkaline earth
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 13
- 229940124597 therapeutic agent Drugs 0.000 title claims 13
- 210000001685 thyroid gland Anatomy 0.000 title claims 13
- 239000004480 active ingredient Substances 0.000 claims 9
- 239000003463 adsorbent Substances 0.000 claims 7
- 239000003963 antioxidant agent Substances 0.000 claims 7
- 230000003078 antioxidant effect Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 150000002496 iodine Chemical class 0.000 claims 2
- 239000005495 thyroid hormone Substances 0.000 claims 2
- 229940036555 thyroid hormone Drugs 0.000 claims 2
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229910021536 Zeolite Inorganic materials 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- -1 alkaline earth metal carbonates Chemical class 0.000 claims 1
- 229910052915 alkaline earth metal silicate Inorganic materials 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 claims 1
- 150000004694 iodide salts Chemical class 0.000 claims 1
- 229950008325 levothyroxine Drugs 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims 1
- 239000001230 potassium iodate Substances 0.000 claims 1
- 229940093930 potassium iodate Drugs 0.000 claims 1
- 235000006666 potassium iodate Nutrition 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
- 229940035722 triiodothyronine Drugs 0.000 claims 1
- 239000010457 zeolite Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Oralno terapijsko sredstvo za štitnjaču, koje sadrži najmanje jedan aktivni sastojak u obliku hormona štitnjače ili njegove farmaceutski prihvatljive soli u kombinaciji s najmanje jednim antioksidansom i najmanje jednim adsorbentom, pri čemu omjer aktivni sastojak: antioksidans: adsorbent u mas.% iznosi 1 : 1: 5 do 1 : 50 : 100,
naznačeno time što je antioksidans odabran od organskih antioksidansa koji sadrže sumpor, pri čemu su organski antioksidanti koji sadrže sumpor odabrani od cisteina, cistina, glutationa, dimerkaptopropan sulfonske kiseline i njihovih soli te od smjesa gore navedenih sredstava i gdje je adsorbent odabran od anorganskih adsorbenata.
2. Oralno terapijsko sredstvo za štitnjaču, u skladu s patentnim zahtjevom 1, naznačeno time što je aktivni sastojak u obliku hormona štitnjače levotiroksina ili njegovih farmaceutski prihvatljivih soli ili liotironina ili njegovih farmaceutski prihvatljivih soli ili gdje su uključene smjese navedenih aktivnih sastojaka.
3. Oralno terapijsko sredstvo za štitnjaču, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što a sadrži daljnji aktivni sastojak, pri čemu je daljnji aktivni sastojak poželjno najmanje jedna jodna sol odabrana od jodida ili jodata alkalnih metala, naročito kalijevog jodida ili kalijevog jodata, i smjesa navedenih jodnih soli.
4. Oralno terapijsko sredstvo za štitnjaču, u skladu s najmanje jednim od prethodnih patentnih zahtjeva, naznačeno time što su nadalje uključene farmaceutski prihvatljive pomoćne tvari, nosači i/ili razrjeđivači.
5. Oralno terapijsko sredstvo za štitnjaču, prema najmanje jednom od prethodnih patentnih zahtjeva, naznačeno time što je organski antioksidans koji sadrži sumpor cistein.
6. Oralno terapijsko sredstvo za štitnjaču, u skladu s patentnim zahtjevom 5, naznačeno time što anorganski bazični ili oksidni adsorbenti odabrani od silikagela, zeolita, oksida zemnoalkalijskih metala, alkalijskih karbonata, alkalnih bikarbonata, karbonata zemnoalkalijskih metala, zemnoalkalijskih bikarbonata, zemnoalkalijskih silikata i smjesa gore navedenih adsorbenata.
7. Oralno terapijsko sredstvo za štitnjaču, u skladu s patentnim zahtjevom 6, naznačeno time što je zemno alkalijski oksid magnezijev oksid i/ili silikat zemnoalkalijskog metala je talk i/ili alkalijski karbonat je natrijev karbonat.
8. Oralno terapijsko sredstvo za štitnjaču, prema najmanje jednom od prethodnih patentnih zahtjeva, naznačeno time što omjer aktivni sastojak: antioksidans: adsorbent u mas.% iznosi 1 : 5 : 5 do 1 : 10 : 40.
9. Oralno terapijsko sredstvo za štitnjaču, prema najmanje jednom od prethodnih patentnih zahtjeva, naznačeno time što sadržaj aktivnog sastojka iznosi 0,01 do 0,5 mas.%.
10. Oralno terapijsko sredstvo za štitnjaču, prema najmanje jednom od prethodnih patentnih zahtjeva, naznačeno time što sadržaj aktivnog sastojka u jednoj dozi iznosi od 25 µg do 150 µg.
11. Oralno terapijsko sredstvo za štitnjaču, prema najmanje jednom od prethodnih patentnih zahtjeva, u obliku tablete koja se može podijeliti jednom ili nekoliko puta.
12. Oralno terapijsko sredstvo za štitnjaču, u skladu s patentnim zahtjevom 11, naznačeno time što djeljiva tableta ima utor za lomljenje, više utora za lomljenje, raspoređenih paralelno jedan s drugim, ili utor za poprečno lomljenje.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017102192 | 2017-02-03 | ||
DE102017122807.1A DE102017122807B4 (de) | 2017-09-29 | 2017-09-29 | Orales Schilddrüsentherapeutikum |
EP18706422.5A EP3576795B1 (de) | 2017-02-03 | 2018-02-02 | Orales schilddrüsentherapeutikum |
PCT/EP2018/052713 WO2018141938A1 (de) | 2017-02-03 | 2018-02-02 | Orales schilddrüsentherapeutikum |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210799T1 true HRP20210799T1 (hr) | 2021-06-25 |
Family
ID=61256901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210799TT HRP20210799T1 (hr) | 2017-02-03 | 2021-05-18 | Oralno terapijsko sredstvo za štitnjaču |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP3576795B1 (hr) |
CN (1) | CN110234356A (hr) |
CR (1) | CR20190352A (hr) |
CY (1) | CY1124264T1 (hr) |
DK (1) | DK3576795T3 (hr) |
DO (1) | DOP2019000199A (hr) |
ES (1) | ES2872249T3 (hr) |
GE (1) | GEP20217241B (hr) |
HR (1) | HRP20210799T1 (hr) |
HU (1) | HUE054988T2 (hr) |
LT (1) | LT3576795T (hr) |
MD (1) | MD3576795T2 (hr) |
NI (1) | NI201900083A (hr) |
PL (1) | PL3576795T3 (hr) |
PT (1) | PT3576795T (hr) |
RS (1) | RS61998B1 (hr) |
SG (1) | SG11201906890TA (hr) |
SI (1) | SI3576795T1 (hr) |
TW (1) | TWI753097B (hr) |
UA (1) | UA124642C2 (hr) |
WO (1) | WO2018141938A1 (hr) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19541128C2 (de) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
PL191399B1 (pl) | 1996-10-28 | 2006-05-31 | Gen Mills Inc | Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka |
DE19830246A1 (de) | 1998-07-07 | 2000-01-13 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
US20030099699A1 (en) | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
GB0316206D0 (en) * | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
US20090297566A1 (en) | 2004-12-27 | 2009-12-03 | Brinkman Kyle R | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions |
CN101305099A (zh) * | 2005-09-08 | 2008-11-12 | 夏尔有限责任公司 | 具有提高的生物利用度的t3和t4的前药 |
ATE501059T1 (de) | 2005-10-05 | 2011-03-15 | Berlin Chemie Ag | Pharmazeutische schutzverpackung |
GB0920041D0 (en) * | 2009-11-16 | 2009-12-30 | Univ Aston | Tablet |
DK2885005T3 (en) * | 2012-08-20 | 2018-01-02 | Merck Patent Gmbh | FIXED PHARMACEUTICAL PREPARATION CONTAINING LEVOTHYROXIN |
US8779000B1 (en) | 2013-07-20 | 2014-07-15 | Nilesh Parikh | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production |
-
2018
- 2018-02-02 GE GEAP201815179A patent/GEP20217241B/en unknown
- 2018-02-02 MD MDE20191355T patent/MD3576795T2/ro unknown
- 2018-02-02 ES ES18706422T patent/ES2872249T3/es active Active
- 2018-02-02 CN CN201880009870.1A patent/CN110234356A/zh active Pending
- 2018-02-02 CR CR20190352A patent/CR20190352A/es unknown
- 2018-02-02 EP EP18706422.5A patent/EP3576795B1/de active Active
- 2018-02-02 LT LTEP18706422.5T patent/LT3576795T/lt unknown
- 2018-02-02 SI SI201830290T patent/SI3576795T1/sl unknown
- 2018-02-02 UA UAA201909466A patent/UA124642C2/uk unknown
- 2018-02-02 PL PL18706422T patent/PL3576795T3/pl unknown
- 2018-02-02 PT PT187064225T patent/PT3576795T/pt unknown
- 2018-02-02 SG SG11201906890TA patent/SG11201906890TA/en unknown
- 2018-02-02 DK DK18706422.5T patent/DK3576795T3/da active
- 2018-02-02 RS RS20210713A patent/RS61998B1/sr unknown
- 2018-02-02 WO PCT/EP2018/052713 patent/WO2018141938A1/de unknown
- 2018-02-02 TW TW107103859A patent/TWI753097B/zh active
- 2018-02-02 HU HUE18706422A patent/HUE054988T2/hu unknown
-
2019
- 2019-07-31 NI NI201900083A patent/NI201900083A/es unknown
- 2019-07-31 DO DO2019000199A patent/DOP2019000199A/es unknown
-
2021
- 2021-05-18 HR HRP20210799TT patent/HRP20210799T1/hr unknown
- 2021-06-17 CY CY20211100541T patent/CY1124264T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP3576795A1 (de) | 2019-12-11 |
CR20190352A (es) | 2019-10-25 |
RS61998B1 (sr) | 2021-07-30 |
GEP20217241B (en) | 2021-04-12 |
SG11201906890TA (en) | 2019-08-27 |
NI201900083A (es) | 2019-10-21 |
EP3576795B1 (de) | 2021-04-07 |
SI3576795T1 (sl) | 2021-07-30 |
LT3576795T (lt) | 2021-07-26 |
UA124642C2 (uk) | 2021-10-20 |
HUE054988T2 (hu) | 2021-10-28 |
PT3576795T (pt) | 2021-06-22 |
CN110234356A (zh) | 2019-09-13 |
DOP2019000199A (es) | 2019-10-31 |
ES2872249T3 (es) | 2021-11-02 |
TWI753097B (zh) | 2022-01-21 |
DK3576795T3 (da) | 2021-06-07 |
CY1124264T1 (el) | 2022-07-22 |
TW201836598A (zh) | 2018-10-16 |
WO2018141938A1 (de) | 2018-08-09 |
MD3576795T2 (ro) | 2021-08-31 |
PL3576795T3 (pl) | 2021-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
AR100925A1 (es) | Composiciones orales que contienen fuentes de ión de zinc, estaño y fluoruro | |
HRP20201685T1 (hr) | Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja | |
PE20130063A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
AR086651A1 (es) | Dentifrico de ion metalico con bajo contenido de agua | |
MX2007008227A (es) | Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos. | |
AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
AR098773A1 (es) | Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla | |
IL276569A (en) | Hypertonic pharmaceutical preparations containing a chemical protective agent against platinum | |
RU2015123446A (ru) | Стабильные композиции, содержащие ион металла | |
PH12015501783A1 (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
BR112014030680A2 (pt) | forma de dosagem efervescente | |
HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
HRP20210799T1 (hr) | Oralno terapijsko sredstvo za štitnjaču | |
AR070593A1 (es) | Composiciones efervescentes | |
JP2019013221A5 (hr) | ||
AR088918A1 (es) | Composiciones antitranspirantes anhidras | |
AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
PE20100154A1 (es) | Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen | |
ES2192136A1 (es) | Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis. | |
RU2010101936A (ru) | Антиоксидантная композиция | |
AR098728A1 (es) | Métodos para tratar la gingivitis usando pasta dental con un alto contenido de sal | |
BRPI0512479A (pt) | composição de pasta de dentes em gel visualmente transparente e método para a obtenção de uma pasta de dentes | |
BRPI1010987B8 (pt) | composições de dosagem sólida de liberação controlada contendo ibuprofeno |